S-ketamine in patient-controlled analgesia reduces opioid consumption in a dose-dependent manner after major lumbar fusion surgery: a randomized, double-blind, placebo-controlled clinical trial

Elina C.V. Brinck[1,2,#a ¶], Taru Virtanen[3,¶, #b], Sanna Mäkelä[4], Venla Soini[5], Ville-Veikko Hynninen[4], Jukka Mulo[4], Urmas Savolainen[4], Juho Rantakokko[5], Kreu Maisniemi[1], Antti Liukas[3], Klaus T. Olkkola[2], Vesa Kontinen[6], Pekka Tarkkila[1], Marko Peltoniemi[3], Teijo I. Saari[3,4, #b]

[1]Department of Anaesthesiology, Töölö Hospital, Division of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

[2]Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

[3]Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland

[4]Division of Perioperative Services, Intensive Care Medicine and Pain Management; Turku University Hospital

[5]Division of the musculoskeletal system at Turku University Hospital, Turku University Hospital, Department of Orthopaedics, University of Turku, Turku, Finland.

[6]Department of Anaesthesiology, Jorvi Hospital, Division of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland

[#a]Current address: Department of Anesthesiology, Töölö Hospital, Helsinki University Hospital, Helsinki, Finland

[#b]Current address: Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland

[¶]Shared equal contribution

*Corresponding author, E-mail: teisaa@utu.fi (TIS)

Abstract

BACKGROUND: Spinal fusion surgery causes severe pain. Strong opioids, commonly

used as postoperative analgesics, may have unwanted side effects. S-ketamine may be

an effective analgesic adjuvant in opioid patient-controlled analgesia (PCA). However,

the optimal adjunct S-ketamine dose to reduce postoperative opioid consumption is still

unknown.

METHODS: We randomized 107 patients at two tertiary hospitals in a double-blinded,

placebo-controlled clinical trial of adults undergoing major lumbar spinal fusion surgery.

Patients were randomly allocated to four groups in order to compare the effects of three

different doses of adjunct S-ketamine (0.25, 0.5, and 0.75 mg ml-1) or placebo on

postoperative analgesia in oxycodone PCA. Study drugs were administered for 24

hours postoperative after which oxycodone-PCA was continued for further 48 hours.

Our primary outcome was cumulative oxycodone consumption at 24 hours after

surgery.

RESULTS: Of the 100 patients analyzed, patients receiving 0.75 mg ml^{-1} S-ketamine in

oxycodone PCA needed 25% less oxycodone at 24 h postoperatively (61.2 mg)

compared with patients receiving 0.5 mg ml^{-1} (74.7 mg) or 0.25 mg ml^{-1} (74.1 mg) S-

ketamine in oxycodone or oxycodone alone (81.9 mg) (mean difference: -20.6 mg; 95%

confidence interval [CI]: -41 to -0.20; P = 0.048). A beneficial effect in mean change of

pain intensity at rest was seen in the group receiving 0.75 mg ml^{-1} S-ketamine in

oxycodone PCA compared with patients receiving lower ketamine doses or oxycodone

alone (standardized effect size: 0.17, 95% CI: 0.013–0.32, $P = 0.033$). The occurrence

of adverse events was similar among the groups.

CONCLUSIONS: Oxycodone PCA containing S-ketamine as an adjunct at a ratio of 1:

0.75 decreased cumulative oxycodone consumption at 24 h after major lumbar spinal

fusion surgery without additional adverse effects.

Introduction

Severe postoperative pain is common after major spinal fusion surgery [1]. Inadequate pain management is associated with increased postoperative complications, delayed ambulation, and chronic postoperative pain [2]. This may lead to unplanned readmission after surgery, decreased patient satisfaction, and increased health-care costs. Opioids have been the cornerstone of postoperative analgesia after major surgery, but the increasing awareness of the problems associated with their use, such as opioid-associated adverse effects, opioid-induced hyperalgesia, and the risk of addiction, combined with the current opioid crisis has encouraged the search for alternative analgesic strategies.

Multimodal analgesia targets different pain signaling pathways by combining two or more analgesic modalities, aiming at additive or even synergistic analgesic effect [3]. Multimodal analgesia has proven feasible after major spinal fusion surgery in an effort to optimize pain relief while minimizing opioid-related adverse effects [4,5].

Patient-controlled analgesia (PCA) use is associated with lower pain intensity and greater patient satisfaction compared with conventional (oral, subcutaneous, or intramuscular) administration routes [6]. PCA may enhance patient autonomy because the analgesic drug is readily available. Morphine is the most frequently used opioid in PCA, while oxycodone use is associated with higher patient satisfaction scores [6,7].

Low-dose (<1 mg kg^{-1}) ketamine inhibits N-methyl-D-aspartate receptors in nociceptive neurons and activates descending inhibitory pain pathways, resulting in attenuated wind up and central sensitization [8-11]. The effect of perioperative intravenous ketamine as

an adjunct analgesic has been documented in several clinical trials and meta-analyses

[12]. A recent review article concluded that combining ketamine with an opioid in IV-

PCA during the postoperative period has a beneficial effect on analgesia and opioid

consumption [13]. In orthopedic surgery, earlier trials found negative or unclear results

with opioid-ketamine PCA [14-16]. However, studies' vast heterogeneity and small

sample sizes have failed to establish a possible a possible dose-responsiveness. Thus,

the optimal ketamine to opioid ratio in intravenous PCA is yet to be elucidated.

We hypothesized that adjunct S-ketamine with oxycodone in an intravenous PCA is

superior to oxycodone, with reduced opioid-associated adverse events in the immediate

postoperative period after major spinal surgery. This randomized, double-blind, placebo-

controlled study compared three different doses of S-ketamine with placebo added as

an adjuvant to oxycodone IV-PCA administered for 24 hours after lumbar spinal fusion

in adult patients. After the study phase, IV oxycodone-PCA without ketamine was

continued for further 48 hours. The primary outcome was cumulative oxycodone

consumption at 24 h after surgery. The secondary endpoints included postoperative

pain intensity, oxycodone consumption, and occurrence of adverse events up to 72 h

after surgery.

Methods

Ethics and registration

This study (DoseRespKeta) was approved by the institutional review board of the Hospital District of Southwest Finland (number: *103/1800/2016*) and the Finnish Medicines Agency (FIMEA, KL 135/2016). The trial was registered before patient enrollment at clinicaltrials.gov (NCT02994173; Principal investigator: TIS; Date of registration: September 11, 2017) and in the EudraCT database (*2016-002887-14*; Principal investigator: TIS; Date of registration: October 12, 2016). No changes to methods were made after trial commencement. The detailed study protocol is available upon request from the authors. Written informed consent was obtained from the participants before inclusion to the study. This manuscript complies with the Consolidated Standards of Reporting Trials guidelines.

Patient population

This two-center study was carried out at the T-hospital and TYKS ORTO units at Turku University Hospital in Turku, Southwest Finland and the HUS Helsinki University Hospital's Töölö Unit in Helsinki, Finland. One hundred and seven adult patients scheduled for elective posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation under general anesthesia were recruited between 6 February 2017 and 31 October 2019 (Fig 1).

Figure 1. DoseRespKeta trial structure and CONSORT 2009 flow diagram. CONSORT

indicates Consolidated Standards of Reporting Trials.

Patients with previous history of intolerance to a study drug, concomitant drug therapy

with strong opioids or strong cytochrome P450 3A4 or 2B6 inductor or inhibitors 2

weeks prior to study, younger than 20 years and older than 80 years, BMI >35, sleep

apnea or any other sleep disorder, existing significant liver or kidney disease, history of

alcoholism, drug abuse, and psychological or other emotional problems likely to

invalidate informed consent were excluded. Patients were pre-screened by a

preoperative care nurse. Potentially eligible subjects were directed to investigators for

further screening and information. ECVB and MP enrolled all participants.

Study design, randomization, and blinding

A randomized, double-blind, controlled dose-response study design was used (Fig 1).

The allocation ratio was 1:1:1:1. Subjects were randomly assigned to one of four dosing

groups (G) for intravenous PCA:

- G1, oxycodone 1 mg ml^{-1} alone

- G2, oxycodone 1 mg ml^{-1} + S-ketamine 0.25 mg ml^{-1} (ratio 1:0.25)

- G3, oxycodone 1 mg ml^{-1} + S-ketamine 0.5 mg ml^{-1} (ratio 1:0.5),

- G4, oxycodone 1 mg ml^{-1} + S-ketamine 0.75 mg ml^{-1} (ratio 1:0.75).

An independent statistician created a computer-generated randomization list. The list

was sent to the local hospital pharmacy, which took care of assignment. Coded PCA

reservoirs with no other markings were delivered to the operation room by the pharmacy

on the day of surgery to ensure double blinding. Patients, researchers, and clinical staff

were blinded to group allocation.

Conduct of the study and anesthesia

After providing written informed consent, patients learned to use the PCA system

(CADD®-Solis VIP and CADD-Legacy® PCA Pump Model 6300, Smiths Medical,

Minneapolis, MN, USA) and numerical rating scale (NRS; 0 denotes no pain, and 10

indicates the worst imaginable pain). Preoperatively, all patients received 1000 mg of

paracetamol orally. Routine anesthetic monitoring included pulse oximetry,

electrocardiography, invasive blood pressure via radial artery cannulation, and body

temperature measurement. General anesthesia was induced and maintained with

propofol (Propofol-Lipuro 20 mg ml^{-1}; B. Braun Melsungen AG, Melsungen, Germany)

and remifentanil (Remifentanil B. Braun 1 mg ml^{-1}; B. Braun Melsungen AG, Melsungen,

Germany) target-controlled infusions. Schnider- and Minto-effect-site models were used

for propofol and remifentanil, respectively [17,18]. No opioids other than remifentanil

were used before or during anesthesia. Rocuronium bromide (Esmeron 10 mg ml^{-1};

Merck Sharp & Dohme B.V., BN Haarlem, The Netherlands) 0.4–0.6 mg kg^{-1} facilitated

endotracheal intubation. The depth of anesthesia (bispectral index BIS or entropy index)

was targeted from 45 to 55 with entropy (GE B850 Monitor Entropy Module, GE,

Helsinki, Finland) or BIS monitor (The Philips BIS module, Philips Medical Systems,

Eindhoven, The Netherlands). Mean arterial pressure (MAP) was maintained at 65–75

mmHg. Intravenous bolus doses of ephedrine and/or noradrenaline infusion were

administered if necessary. Local anesthetic was injected to the skin incision area before

incision (lidocaine 5 mg kg^{-1} c. adrenaline 5 μg kg^{-1}; Orion Pharma, Espoo, Finland) and

after wound closure (levobupivacaine 2.5 mg kg^{-1}; Chirocaine 2.5 mg ml^{-1}, AbbVie S.r.l.,

Campoverde di Aprilia, Italy) as per hospital routines.

At the end of surgery, the PCA pump was attached to the intravenous line and

activated. The first dose of PCA solution was given just after the cessation of propofol

and remifentanil infusions, before patients woke up from anesthesia. As soon as the

patient awoke, they were encouraged to use PCA to treat postoperative pain if

necessary. The starting dose of oxycodone (Oxycodone Orion 10 mg ml^{-1}; Orion

Pharma, Espoo, Finland) in the PCA solution was 2 mg with a lockout interval of 5 min.

When NRS was 4 or lower, the PCA oxycodone dose was decreased to 1 mg (G1–G4).

The study PCA dosing continued for 24 h from the end of surgery, after which the PCA

cassettes were changed in all study groups and contained only 1 mg/ml oxycodone

thereafter in all study groups.

The total duration of PCA treatment was three days. Postoperative nausea and vomiting

(PONV) were treated with intravenous ondansetron and dehydrobenzperidol if

necessary. Intravenous bolus of lorazepam (1mg) was administered if a patient had

unpleasant psychomimetic symptoms.

Measurements and data handling

Heart rate, blood pressure, respiratory rate, peripheral oxygen saturation, NRS (0–10)

for pain intensity at rest and upon movement, level of sedation with the Richmond

Agitation-Sedation scale (RASS), nausea, vomiting, pruritus, unpleasant dreams or any

other adverse effect or sensation thought to be caused by PCA, cumulative PCA

pressings, or the doses given were registered immediately after arrival in the recovery

room and at the following time points: five, 30, 60 , 120, and 240 minutes and eight, 24,

48, and 72 hours later. Patients evaluated their pain relief satisfaction (yes/no) at the

end of postoperative days 1–3.

All clinical patient data were collected on individual case report forms. All data were

subsequently transferred to electronic format for exploratory data analysis.

Primary and secondary outcomes

The primary endpoint was cumulative oxycodone consumption at 24 h after surgery, the

end of period when three different ratios of S-ketamine were added to oxycodone PCA

solution.

Secondary outcomes were NRS and RASS ratings, oxycodone consumption, PONV,

pruritus, and unpleasant dreams or other adverse effects.

Sample size calculation

Based on a previous study [19], we calculated that 25 patients per group were

necessary to demonstrate a clinically significant 25% reduction in oxycodone

consumption with a level of significance of $P = 0.05$ and power of 80%.

Statistical analyses

The authors approved the statistical analysis plan before the analyses began.

Explorative data analysis was conducted before statistical inference by plotting and

tabulating the data. Normality assumptions were tested before analysis, using probit

plots and the Shapiro–Wilk W-test. Levene's test was used to evaluate homogeneity of

variances.

The primary outcome measure, cumulative opioid consumption during the first 24 h is

presented as both median and interquartile range (IQR; Q1–Q3) and mean (SD).

Cumulative opioid consumption at 24, 48, and 72 h was analyzed by using a linear

mixed model for repeated measurements. The model included the following factors:

PCA dosing groups G1–G4, age (as a continuous covariate), age, gender, prior use of

opioids (yes/no), prior use of gabapentinoids (yes/no), cumulative amount of dose

requests during PCA, and postoperative time (24, 48, and 72 h). In addition, the

interaction with time and opioid consumption and prior use of weak opioids was

examined. Non-significant terms were excluded from the final model. An unstructured

covariance structure was used. Square-root transformation was used to fulfill

assumptions of the model. Studentized residuals were used to check assumptions.

To study pain burden, we analyzed if the mean change in NRS over time differed

between the groups during the first 24 hours postoperatively. A hierarchical linear mixed

model was used including time as a within-factor (with five time points), PCA dosing

group as a between-factor, and their interaction. The time factor was handled as

categorical to estimate all possible shapes of mean changes over time. NRS values

were standardized before analysis by centering and scaling to have a mean of zero and

a SD of one. Effect sizes were computed as the eta squared based on the H-statistic

[20]. We also studied in a separate model, whether age, sex, weight, chronic pain, and

prior use of weak opioids or gabapentinoids affected the results. Differences in NRS

and sedation (measured with RASS) between the groups were evaluated at the end of

post-anesthesia care unit (PACU) treatment (t = 480 min) and at 24 h with a Kruskal–

Wallis test.

Differences in postoperative nausea and vomiting, pruritus, and unpleasant dreams

(yes/no) among groups at 24, 48, and 72 h postoperatively were evaluated with ordinal

logistic regression. The effect of age, sex, weight, chronic pain, and prior use of weak

opioids or gabapentinoids on the results were tested as covariate effects. To analyze

the effect of adjuvant ketamine treatment on these parameters, we included changes in

parameters to the model during the previous 24 h.

Descriptive statistics are shown as means and SD when variables are normally

distributed and otherwise as medians and IRQs. Categorical variables are summarized

as counts and percentages. The statistical significance level was set to P <0.05.

RStudio (version 1.0.153) [21] with R (version 3.6.0) [22] and ggplot2 (version 2.2.1)

were used for statistical analyses and graphical presentations.

Results

A total of 231 patients were assessed for eligibility. 107 patients were recruited in the study (Fig 1B) between February 2017 and October 2019. Two patients withdrew their consent before randomization and were excluded. Two patients were further excluded due to logistical reasons before surgery. In one case, the operation plan was changed after randomization and this patient was also excluded from the study. Two more patients withdrew consent during the first 24 h after the start of intervention and were excluded from the final analysis. Thus, 25 patients in each of the four groups were included in the analysis. Patient median age was 60 (28–78) years and 77% were women. No significant differences in baselines characteristics were present among the groups (Table 1).

251 **Table 1.** Perioperative Data and Characteristics of Patients Who Were Included in the Analysis.

	All	G1	G2	SMD Between G1 and G2	G3	SMD Between G1 and G3	G4	SMD Between G1 and G4
n	100	25	25		25		25	
Age, yr (median, range)	60 (28-78)[2]	56 (34-78)	62 (28-76)	0.214	60 (40-75)	0.433	62 (30-76)	0.329
Female/male, n (%)	45/55	11/14 (44%)[1]	11/14 (44%)	<0.001	12/13 (48%)	<0.001	11/14 (44%)	0.08
Body weight (kg)	77.7 (15.6)	77.7 (15.6)	74.9 (15.9)	0.215	79.0 (14.1)	0.278	77.0 (11.2)	0.156
BMI (kg/m^{-2})	26.9 (4.3)	26.6 (4.6)	27.3 (4.3)	0.003	26.9 (3.5)	0.152	26.8 (4.9)	0.063
Smoking (yes/no), n (%)	9/91	1/24 (4%)[1]	3/22 (12%)	0.169	3/22 (12%)	0.298	2/23 (7.7%)	0.298
Previous chronic pain (yes/no), n (%)	15/85	22/3 (88%)[1]	19/6 (76%)	0.115	22/3 (88%)	0.316	22/3 (88%)	<0.001
Median [IRQ] preoperative pain intensity (NRS)	6 [4, 8]	6 [5, 7]	5 [5, 7]	0.1	7 [5, 8]	0.42	7 [5, 8]	0.023
Preoperative opioid (yes/no), n (%)	5/94	2/23 (8.0%)[1]	2/23 (8.0%)	0.169	0/25 (0%)	<0.001	1/24 (3.8%)	0.417
Preoperative gabapentinod (yes/no), n (%)	18/82	3/22 (12%)[1]	3/22 (12%)	0.22	7/18 (28%)	<0.001	5/20 (19%)	0.408
Diabetes (yes/no), n (%)	8/92	1/24 (4.0%)[1]	3/22 (12%)	0.169	1/25 (4.0%)	0.298	3/22 (11%)	<0.001
ASA physical status, n (%)				0.408		0.182		0.331
1	24	7 (28.0)	6 (24.0)		6 (24.0)		5 (20.0)	
2	66	17 (68.0)	15 (60.0)		17 (68.0)		17 (68.0)	
3	10	1 (4.0)	4 (16.0)		2 (8.0)		3 (12.0)	
Duration of surgery (min)	306 (94)	325 (89)	292 (64)	0.424	303 (125)	0.202	305 (89)	0.226

Propofol during surgery (mg·kg⁻¹)	37 (12)	39 (11)	36 (8)	0.259	35 (17)	0.26	36 (10)	0.248
Remifentanil during surgery (μg·kg⁻¹·min⁻¹)	0.12 (0.05)	0.13 (0.06)	0.12 (0.04)	0.27	0.11 (0.04)	0.429	0.11 (0.04)	0.383

Data are mean (standard deviation) or [range) unless otherwise stated. Standardized difference is the difference in the mean of a

variable between 2 groups divided by an estimate of the standard deviation of that variable [22].

G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine

0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled

intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25); SMD, standardized mean deviation; n, number of non-missing value;

BMI, body-mass index; IQR, interquartile range; NRS, numerical rating scale; ASA, American Society of Anesthesiologists.

[1]Percentage of females or yes-answers

Opioid consumption

Cumulative oxycodone consumption was highest in group G1 and lowest in G4 (Fig 2, Table 2). The median total oxycodone consumption during the first 24 h after surgery was 81.9 mg (IQR: 63.2–101), 74.1 mg (IQR: 62.1–86.1), 74.7 mg (IQR: 62.2–87.1), and 61.3 mg (IQR: 48.7–73.8) in groups G1–G4, respectively. Postoperative cumulative oxycodone consumption was significantly reduced in the group with the highest ketamine concentration (G4) compared with the control group (G1): the mean difference was -21 mg (95% CI: -41 to -0.2, $P = 0.048$), -26 mg (95% CI: -55 to -6.2, $P = 0.044$) and -41 mg (95% CI: -68 to -14, $P = 0.003$) at 24, 48, and 72 h after surgery, respectively (Fig 2). There was no significant difference in time to dose reduction from 2 mg to 1 mg PCA-bolus among groups (median [IQR]: 125 min [78–203], 127 min [82–174], 112 min [69–185] and 145 min [79–211] in groups G1–G4, respectively, $P = 0.838$).

Figure 2. Postoperative cumulative oxycodone (*top row*) and S-ketamine (*bottom row*)

consumption during the first 24 h in four patient-controlled analgesia (PCA) treatment groups

(G1¬–G4). PCA, patient-controlled analgesia. Box plots show the median and 25–75th

percentiles, and the whiskers indicate the minimum and maximum. Blue diamonds show the

mean oxycodone consumption in each plot.

279 **Table 2**. Oxycodone consumption during the study after the beginning of PACU care

Time after PACU start	All (n=100)	G1 (n=25)	G2 (n=25)	G3 (n=25)	G4 (n=25)
60 min					
Mean (SD)	10.9 (4.2)	11.9 (3.4)	10.3 (3.9)	11.3 (4.2)	10.4 (5.1)
Median [IRQ]	10.0 [8.00, 14.0]	12.0 [8.0, 16.0]	10.0 [7.40, 14.0]	10.0 [8.0, 14.0]	12.0 [6.00, 14.0]
120 min					
Mean (SD)	19.2 (7.2)	21.2 (6.6)	18.2 (5.6)	20.0 (8.5)	17.3 (7.5)
Median [IRQ]	18.0 [14.0, 24.0]	21.0 [16.0, 25.0]	18.0 [16.0, 22.0]	18.0 [13.3, 24.0]	15.0 [12.0, 24.0]
240 min					
Mean (SD)	28.2 (12.5)	31.0 (13.0)	26.5 (9.3)	28.6 (14.8)	26.7 (12.6)
Median [IRQ]	26.8 [20.0, 35.0]	28.0 [25.0, 35.0]	26.6 [23.0, 34.0]	24.0 [18.0, 36.0]	26.0 [18.0, 34.0]
480 min					
Mean (SD)	37.6 (16.7)	39.6 (16.9)	36.4 (13.1)	39.1 (18.3)	35.5 (18.5)
Median [IRQ]	35.5 [26.8, 46.3]	37.0 [31.0, 44.0]	34.0 [29.0, 49.0]	33.0 [26.0, 49.0]	36.0 [23.0, 45.0]
24 h					
Mean (SD)	72.9 (36.5)	81.9 (47.6)	74.1 (30.7)	74.7 (31.8)	61.3 (32.3)
Median [IRQ]	65.0 [46.8, 93.7]	65.0 [55.0, 104]	71.0 [48.0, 93.6]	71.0 [51.3, 93.0]	51.0 [42.0, 78.0]
48 h					
Mean (SD)	117 (74.0)	137 (96)	118 (67.5)	121 (63.6)	90.8 (57.3)
Median [IRQ]	99.0 [65.2, 136]	118.0 [73.2, 147]	94.3 [73.2, 135]	112.0 [72.0, 130]	73.5 [52.0, 120]
72 h					
Mean (SD)	145 (95.6)	170 (123)	156 (97.7)	146 (67.0)	109 (73.3)

Median [IRQ]	127 [77.5, 170]	150 [88.2, 170]	128 [90.0, 189]	129 [97.0, 178]	89.0 [56.8, 147]

PACU, postoperative care unit, G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).

Cumulative S-ketamine consumption at 24, 48 and 72 h

Cumulative S-ketamine consumption was highest in group G1 and lowest in G4 (Fig

2b). The median total S-ketamine consumption during the first 24 h after surgery was

17.8 mg (IQR: 12.0–23.4), 35.5 mg (IQR: 25.7–46.5), and 38.25 mg (IQR: 31.5–58.5) in

groups G2–G4, respectively. During the follow-up S-ketamine remained nearly the

same between G4 and G3 (Table 3)

Table 3. Cumulative S-ketamine consumption during the study after the beginning of PACU

care

Time after PACU start	G1 (n=25)	G2 (n=25)	G3 (n=25)	G4 (n=25)
24 h				
Mean (SD)	0.0 (0.0)	18.5 (7.7)	37.4 (15.9)	45.9 (24.2)
Median [IRQ]	0.0 [0.0, 0.0]	17.8 [12.0, 23.4]	35.5 [25.7, 46.5]	38.3 [31.5, 58.5]
48 h				
Mean (SD)	0.0 (0.0)	28.9 (16.8)	57.7 (33.6)	66.4 (38.4)
Median [IRQ]	0.0 [0.0, 0.0]	23.4 [17.0, 31.8]	53.8 [35.0, 64.5]	55.1 [39.0, 89.8]
72 h				
Mean (SD)	0.0 (0.0)	37.3 (24.1)	66.4 (38.4)	81.6 (55.0)
Median [IRQ]	0.0 [0.0, 0.0]	29.8 [22.0, 46.0]	63.7 [45.9, 85.3]	66.8 [42.6, 111]

PACU, postoperative care unit, G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25);

G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.25 mg/ml (n=25); G3,

Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient

controlled intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).

Acute pain measurements during postoperative care

There was a small yet statistically significant mean change in postoperative NRS

measured at rest over the first 24 h between groups G4 and G1 (standardized effect

size: 0.17, 95% CI: 0.013–0.32, *P* = 0.033), but not between group G3 and G1

(standardized effect size: -0.097, 95% CI: -0.25–0.059, *P* = 0.223) or G2 and G1

(standardized effect size -0.052, 95% CI: -0.21–0.10, *P* = 0.51) (Fig 3A). Age, sex,

weight, chronic pain, and prior use of weak opioids or gabapentinoids had no effect on

the results.

Figure 3. A) Patient-reported numerical rating scale (NRS) values at rest during the first 24 h in

four patient-controlled analgesia (PCA) treatment groups G1-G4. Box plots show the median

and 25–75th percentiles, and the whiskers indicate the minimum and maximum. (B) Risk ratios

(95% CI) for reporting NRS value 4 or higher. PACU, postoperative care unit; CI, confidence

interval.

To evaluate the effect of pain ratings as a surrogate for patient satisfaction, we analyzed

the risk of having NRS >3 at rest at different timepoints during PACU treatment. For this

purpose, NRS values were dichotomized depending on the pain level that patients

experienced (NRS >3 or NRS ≤3). Although patient satisfaction, measured by patient-

reported NRS was smaller in groups G2–G4 than group G1 at the end of PACU

treatment, the finding was not statistically significant (Fig 3B).

Postoperative sedation

At arrival to PACU, median (IQR) RASS was -1 (-2–0), and all patients were

cooperative. RASS increased to 0 (-1 to 0) within the following 30 minutes. After 60

minutes, all patients were fully awake (median [IQR] RASS: 0 [0, 0]), and they remained

fully awake until the end of the study. No significant differences in RASS scores were

present between the groups during the 72-hour follow-up (Table 4).

Table 4. Opioid related adverse events during the study.

Adverse effect		All	G1	G2	G3	G4
Sedation (RASS-scale)						
0 min		-1 [-2, 0][1]	-1 [-2, 0]	-1 [-3, 0]	-1 [-1,0]	-1 [-2, 0]
5 min		-1 [-2, 0]	-1 [-2, 0]	0 [-1, 0]	0 [0,-1]	-1 [-1, 0]
30 min		0 [0, 1]	0 [0,-1]	0 [-1, 0]	0 [-1, 1]	0 [-1, 0]
60 min		0 [0, 0]	0 [0,-1]	0 [0, 0]	0 [0, 0]	0 [0, 0]
2 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
4 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
8 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
24 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
PONV		n=100	n=23	n=25	n=25	n=25
24 hr	Yes (%)	16 (16)	2 (8)	3 (12)	6 (24)	5 (22)
48 hr	Yes (%)	11 (11)	2 (8)	1 (4)	5 (20)	3 (13)
72 hr	Yes (%)	11 (11)	2 (8)	1 (4)	5 (20)	3 (13)
Pruritus		n=100	n=25	n=25	n=25	n=25
24 hr	Yes (%)	16 (16)	4 (16)	7 (28)	4 (16)	1 (4)
48 hr	Yes (%)	10 (10)	4 (16)	4 (16)	1 (4)	1 (4)

72 hr	Yes (%)	7 (7)	2 (8)	1 (4)	2 (8)	2 (8)

Unpleasant dreams		n=100	n=25	n=25	n=25	n=25
24 hr	Yes (%)	9 (9)	2 (8)	2 (8)	2 (8)	3 (12)
48 hr	Yes (%)	10 (10)	4 (16)	4 (16)	1 (4)	1 (4)
72hr	Yes (%)	7 (7)	2 (8)	1 (4)	2 (8)	2 (8)

[1] RASS-scale given as median [interquartile range]

RASS, Richmond Agitation-Sedation Scale; PONV, postoperative nausea and vomiting; G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).

Opioid-related adverse effects

Opioid-related adverse events during the study are summarized in Table 4. Nausea and vomiting were the most frequent adverse events. At 24 h after PCA start, 16% of patients (n = 16) reported nausea. Increasing ketamine dose seemed to increase the incidence of PONV, but the changes were not statistically significant. Similarly, no differences were seen at the end of 48- and 72-h follow-up. We analyzed these adverse effects further with logistic regression. Our results indicate that preoperative weak opioid use increased the incidence of PONV significantly (odds ratio: 9.23, 95% CI: 1.4–75). Adjuvant ketamine in PCA had no effect (odds ratio: 3.9, 95% CI: 0.68–4.7) on PONV, and after changing to normal PCA with only oxycodone at 24 h, the incidence of PONV did not change (odds ratio: 0.53, 95% CI: 0.62–4.7).

At 24 h after PCA start, 16% of patients (n = 16) reported pruritus (Table 4). The PCA

treatment groups did not show statistically significant differences at any of the three time

points (24, 48, or 72 h after the start of PCA). Similarly, the incidence of pruritus did not

change after changing to normal PCA with oxycodone only.

Nine patients (9%) reported nightmares or unpleasant dreams (Table 4). The groups

showed no difference in this regard, and the incidence did not change after changing to

normal PCA with oxycodone only. Age, sex, weight, chronic pain, and prior use of

gabapentinoids had no effect on the results.

Other adverse effects

There were no severe adverse effects. None of the patients developed respiratory

insufficiency requiring invasive or non-invasive ventilation during the 72-h study period.

No rescue medications were required during the study.

Discussion

This randomized, double-blind, placebo-controlled study evaluated the effect of adding incremental doses of S-ketamine to oxycodone PCA in patients who underwent major lumbar spinal fusion surgery. Our results demonstrate that patients who received oxycodone:S-ketamine ratio 1:0.75 (a bolus containing oxycodone 1 mg + S-ketamine 0.75mg per ml) for postoperative analgesia consumed significantly less oxycodone postoperatively compared with participants who received lower S-ketamine doses or oxycodone alone. This oxycodone sparing effect was achieved with a mean 45.9 mg of S-ketamine during the first 24 h after lumbar spinal fusion surgery.

Additionally, there was a significant opioid sparing effect long after the S-ketamine was removed from PCA at 24 h postoperatively among patients who received oxycodone:S-ketamine ratio 1:0.75 compared with participants in other groups. This could be associated with the long-term antagonism of the NMDA-receptor or the recently proposed analgesic action of active metabolites [24].

A statistically significant effect in mean change in pain intensity at rest was seen in the group receiving 0.75 mg ml^{-1} S-ketamine in oxycodone PCA compared with patients receiving lower doses of ketamine or oxycodone alone. Cumulative oxycodone dose or adjunct S-ketamine did not significantly influence postoperative nausea and vomiting, which could be explained by the low cumulative consumption of oxycodone and ketamine in this group compared to others. Occurrence of pruritus, nightmares, or unpleasant dreams did not differ significantly among study groups.

Major spinal surgery is increasing in frequency and complexity. It is associated with

severe postoperative pain [1], which is not easily amenable to regional anesthesia and

requires a multimodal approach. This is a crowded field of clinical research, with many

previous studies evaluating various single doses of ketamine with different opioids in

many types of surgery. Yet, there is little previous data that assesses the effect of

adjunct ketamine to an IV opioid-PCA exclusively after lumbar spinal fusion surgery in

an opioid-naïve patient population. A recent review and meta-analysis evaluated the

effect of perioperative ketamine for analgesia in spine surgery [25]. However, in most of

the included trials, ketamine was administered intraoperatively followed by

postoperative IV-PCA or ketamine was given both as a pre-incisional bolus and as a

postoperative IV-PCA with a background infusion and a bolus on-demand [26,27]. This

may confuse evaluation of the analgesic effect of IV-PCA administration of ketamine

with an opioid. Additionally, the meta-analysis included patients undergoing lumbar

microdiscectomy with postoperative opioid IV-PCA [28]. It could be anticipated that pain

after lumbar microdiscectomy is less severe than after major lumbar spinal fusion

surgery, and thus postoperative conditions are not comparable. Furthermore, one

previous study was an open-label trial [29] and another had only female patients [30],

making it difficult to generalize results.

Previous studies have shown an opioid-sparing effect of intravenous low-dose ketamine

after spine surgery in opioid-dependent patients [31,32]. Additionally, Loftus (2010) and

Nielsen (2017) showed that the benefit of ketamine increased with the amount of

preoperatively administered opioids [31,32]. Recently Nielsen et al. (2019) showed that

perioperative intravenous S-ketamine reduced analgesic use and pain and improved

labor market attachment of opioid-dependent patients one year after spine surgery [33].

Another recent study further confirmed that postoperative low-dose ketamine infusion

reduced hydromorphone requirements for the first 24 h after spinal fusion surgery in

opioid-tolerant patients, but not in opioid-naïve patients [34]. However, it is recognized

that previous opioid use alters pain processing, and these patients typically require

higher opioid doses postoperatively. Thus, results of these studies cannot be directly

applied to all patients.

Although the effect of adjunct ketamine in the opioid-tolerant patient population after

lumbar fusion surgery is quite well established, the effect in the opioid-naïve population

is less clear. Additionally, the optimal dose of adjunct ketamine in an opioid IV-PCA is

unknown. Data indicating low incidence of ketamine-related adverse events (PONV and

CNS adverse events) has been consistent in previous studies [11,12,35]. Likewise, our

study showed that adjunct S-ketamine in oxycodone IV-PCA was well tolerated. There

are several reports of ketamine's beneficial effect on analgesia, opioid-sparing, and

PONV in the postoperative period, without increasing the risk for hallucinations.

However, the opioid:ketamine ratio in IV-PCA in previous studies was heterogeneous,

ranging from 1:0.5 to 1:2.5, and these studies were also heterogeneous in regard to the

opioid used, anesthesia methodology, type of surgery, patient population, and use of

racemic- or S-ketamine [35,36].

Our study has limitations. Our study was designed to detect a difference in 24 h

cumulative oxycodone consumption, which was the primary outcome. The beneficial

effect of adjunct S-ketamine in an oxycodone IV-PCA in reducing the 24 h oxycodone

consumption did not correlate with a reduction in opioid-related side effects, but this

could be secondary to a lack of power. On the other hand, the strengths of our study

include that the patient population was homogenous across study groups, consisting of

adult men and women who underwent posterolateral lumbar spine fusion with bilateral

transpedicular screw instrumentation.

Postoperative analgesic consumption as a surrogate measure for pain has been

criticized on the basis of reports that it is skewed, where a minority of patients consume

more than half of the postoperative analgesic. A recent study encouraged reporting

categorized parameters as more clinically intuitive [37]. As discussed before,

dichotomizing continuous measures leads to several problems [38]. Previously,

analgesic consumption has been analyzed with point estimates or determining area

under the curve, but both of these methods introduce considerable bias. Statisticians

recommend using a model-based approaches, which has been used here. Therefore,

both mean (SD) and median (IQR) have been reported. From a clinical perspective, it

may be unrealistic to achieve a totally pain-free state after major surgical trauma

following surgery such as instrumented lumbar spinal fusion. We think that IV-PCA

enables the patient to titrate the opioid to reach a certain individual, tolerable pain

intensity level. Therefore, we consider that changes in cumulative opioid consumption

could serve as an acceptable surrogate for changes in postoperative pain. However, we

also evaluated the outcome by using risk ratios for pain intensity NRS >3 as a surrogate

for perioperative pain experience, and adjunct S-ketamine seemed to decrease the

likelihood of pain exceeding NRS >3.

Our study adds new data considering the optimal dose of adjunct S-ketamine to an

oxycodone IV-PCA after lumbar spinal fusion surgery. Because the oxycodone:S-

ketamine ratio of 1:0.75 was not associated with increased adverse events, we suggest

that future studies aimed at solving the optimal opioid:S-ketamine ratio evaluate that

dose and higher, possibly with pharmacokinetic testing to characterize the dose-

concentration-effect relationship.

In conclusion, IV-PCA containing adjunct S-ketamine with oxycodone at a ratio of 1:0.75

after major lumbar spinal fusion surgery is effective in decreasing the total oxycodone

consumption at 24 h after surgery. This oxycodone:S-ketamine ratio is also well

tolerated. As previous studies have mainly focused on intraoperative administration,

even showing no analgesic effect of intraoperative S-ketamine in opioid-naïve patients

[39], this finding adds new data to the feasibility of adjunct S-ketamine with oxycodone

for postoperative pain management after major lumbar spinal fusion surgery.

Acknowledgments

Eliisa Löyttyniemi, MSc, Institute of Biomedicine, University of Turku gave invaluable statistical help. The nursing staff of K- and T-operating units, TYKS ORTO, and neurosurgical wards at Turku University Hospital (Turku, Finland) and the staff of surgical ward 2 and the anesthesia nurses of the Department of Orthopaedics and Trauma Surgery at Töölö Hospital (Helsinki, Finland) are acknowledged for their support conducting the study. Sini Alanko, RN; Toni Broman, RN; Virva Kuusisto, RN; and Jaana Virtanen, RN are thanked for their help at the preoperative clinic. Tuula Eklund, RN; Ulla Simola, RN; and Saku Koskinen, RN are acknowledged for their generous help with the patient data system. Local hospital pharmacies in Turku and Helsinki University Hospitals are acknowledged, and ward pharmacists Anne Honkanen, Kira Honkanen, Elina Luoto, Leea Rissanen, Mari Saalasti and Reija Silvennoinen are thanked for fruitful collaboration.

References

1. Gerbershagen HJ, Aduckathil S, van Wijck AJM, Peelen LM, Kalkman CJ, Meissner W. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. *Anesthesiology*. 2013;118:934–944.

2. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. *Lancet.* 2006;367:1618–1625.

3. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. *Anesth Analg.* 2003;97:534–540.

4. Kurd MF, Kreitz T, Schroeder G, Vaccaro AR. The role of multimodal analgesia in spine surgery. *J Am Acad Orthop Surg.* 2017;25:260–268.

5. Cozowicz C, Bekeris J, Poeran J, Zubizarreta N, Schwenk E, Girardi F, et al. Multimodal pain management and postoperative outcomes in lumbar spine fusion surgery: a population-based cohort study. *Spine* (Phila Pa 1976). 2020;45:580–589.

6. McNicol E, Ferguson MC, Hudcova J. Patient-controlled analgesia versus non-patient controlled analgesia for postoperative pain. *Cochrane Database Syst Rev.* 2015;6:CD003348.

7. Dinges HC, Otto S, Stay DK, Bäumlein S, Waldmann S, Kranke P, et al. Side effect rates of opioids in equianalgesic doses via intravenous patient-controlled analgesia: a systematic review and network meta-analysis. *Anesth Analg.* 2019;129:1153–1162.

8. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical

pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. *Clin*

Pharmacokinet. 2016;55:1059–1077.

9. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular

mechanisms of pain. *Cell.* 2009; 139:267–284.

10. Hirota K, Lambert DG. Ketamine: new uses for an old drug? *Br J Anaesth.*

2011;107:123–126.

11. Woolf CJ. Pain amplification—a perspective on the how, why, when, and where of

central sensitization. *J Appl Biobehav Res.* 2018;23:e12124.

12. Brinck EC, Tiippana E, Heesen M, Bell RF, Straube S, Moore RA, et al.

Perioperative intravenous ketamine for acute postoperative pain in adults.

Cochrane Database Syst Rev. 2018;12:CD012033.

13. Assouline B, Tramèr MR, Kreienbühl L, Elia N. Benefit and harm of adding

ketamine to an opioid in a patient-controlled analgesia device for the control of

postoperative pain: systematic review and meta-analyses of randomized controlled

trials with trial sequential analyses. *Pain.* 2016;157:2854–2864.

14. Sveticic G, Gentilini A, Eichenberger U, Luginbühl M, Curatolo M. Combinations of

morphine with ketamine for patient-controlled analgesia: a new optimization

method. *Anesthesiology.* 2003;98:1195–11205.

15. Sveticic G, Eichenberger U, Curatolo M. Safety of mixture of morphine with

ketamine for postoperative patient-controlled analgesia: an audit with 1026

patients. *Acta Anaesthiol Scand.* 2005;49:870–875.

16. Sveticic G, Farzanegan F, Zmoos P, Zmoos S, Eichenberger U, Curatolo M. Is the combination of morphine with ketamine better than morphine alone for postoperative intravenous patient-controlled analgesia? *Anesth Analg.* 2008;106:287–293, table of contents.

17. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C, Goodale DB, et al. The influence of age on propofol pharmacodynamics. *Anesthesiology.* 1999; 90:1502–1516.

18. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Billard V, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. *Anesthesiology.* 1997; 86:10–23.

19. Lin T-F, Yeh Y-C, Lin F-S, Wang Y-P, Sun W-Z, Fan S-F. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. *Br J Anaesth.* 2009;102:117–122.

20. Tomczak M, Tomczak E. The need to report effect size estimates revisited. An overview of some recommended measures of effect size. *Trends Sport Sci.* 2014;1:19–25.

21. RStudio Team. RStudio: Integrated Development Environment for R. 2020. Available at: http://www.rstudio.com/. Accessed: 13 March, 2020.

22. R Core Team. R: A Language and Environment for Statistical Computing. 2019. Available at: http://www.r-project.org/. Accessed: 13 March 2020.

23. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. *Commun Stat Simul Comput.* 2009;38:1228–1234.

540   24.   Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P et al.

541   Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic

542   Mechanisms. *Pharmacol Rev.* 2018;70:621-660.

543   25.   Pendi A, Field R, Farhan S-D, Eichler M, Bederman SS. Perioperative ketamine

544   for analgesia in spine surgery: a meta-analysis of randomized controlled trials.

545   *Spine (Phila Pa 1976).* 2018; 43:E299–E307.

546   26.   Pacreu S, Fernández Candil J, Moltó L, Carazo J, Fernández Galinski S. The

547   perioperative combination of methadone and ketamine reduces post-operative

548   opioid usage compared with methadone alone. *Acta Anaesthiol Scand.*

549   2012;56:1250–1256.

550   27.   Yeom JH, Chon M-S, Jeon WJ, Shim J-H. Perioperative ketamine with the

551   ambulatory elastometric infusion pump as an adjuvant to manage acute

552   postoperative pain after spinal fusion in adults: a prospective randomized trial.

553   *Korean J Anesthesiol.* 2012;63:54–58.

554   28.   Javery KB, Ussery TW, Steger HG, Colclough GW. Comparison of morphine and

555   morphine with ketamine for postoperative analgesia. *Can J Anaesth.*

556   1996;43:212–215.

557   29.   Nitta R, Goyagi T, Nishikawa T. Combination of oral clonidine and intravenous

558   low-dose ketamine reduces the consumption of postoperative patient-controlled

559   analgesia morphine after spine surgery. *Acta Anaesthesiol Taiwan.* 2013;51:14–

560   17.

561   30.   Song JW, Shim JK, Song Y, Yang SY, Park SJ, Kwak YL. Effect of ketamine as an

562   adjunct to intravenous patient-controlled analgesia, in patients at high risk of

postoperative nausea and vomiting undergoing lumbar spinal surgery. *Br J*

Anaesth. 2013;111:630–635.

31. Loftus RW, Yeager MP, Clark JA, Brown JR, Abdu WA, Sengupta DK. et al.

Intraoperative ketamine reduces perioperative opiate consumption in opiate-

dependent patients with chronic back pain undergoing back surgery.

Anesthesiology. 2010;113:639–646.

32. Nielsen RV, Fomsgaard JS, Siegel H, Martuseviicius R,Nikolajsen L, Dahl JB, al.

Intraoperative ketamine reduces immediate postoperative opioid consumption

after spinal fusion surgery in chronic pain patients with opioid dependency: a

randomized, blinded trial. *Pain.* 2017;158:463–470.

33. Nielsen RV, Fomsgaard JS, Nikolajsen L, Dahl JB, Mathiesen O. Intraoperative S-

ketamine for the reduction of opioid consumption and pain one year after spine

surgery: a randomized clinical trial of opioid-dependent patients. *Eur J Pain.*

2019;23:455–460.

34. Boenigk K, Echevarria GC, Nisimov E, Bergen Granell AE von, Cuff GE, Wang J,

Atchabahian A. Low-dose ketamine infusion reduces postoperative

hydromorphone requirements in opioid-tolerant patients following spinal fusion: a

randomised controlled trial. *Eur J Anaesthesiol.* 2019;36:8–15.

35. Wang L, Johnston B, Kaushal A, Cheng D, Zhu F, Martin J. Ketamine added to

morphine or hydromorphone patient-controlled analgesia for acute postoperative

pain in adults: a systematic review and meta-analysis of randomized trials. *Can J*

Anaesth. 2016;63:311–325.

36.   Carstensen M, Møller AM. Adding ketamine to morphine for intravenous patient-

controlled analgesia for acute postoperative pain: a qualitative review of

randomized trials. *Br J Anaesth.* 2010;104:401–406.

37.   Moore RA, Mhuircheartaigh RJN, Derry S, McQuay HJ. Mean analgesic

consumption is inappropriate for testing analgesic efficacy in post-operative pain:

analysis and alternative suggestion. *Eur J Anaesthesiol.* 2011;28:427–432.

38.   Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ.*

2006;332:1080.

39.   Brinck ECV, Maisniemi K, Kankare J, Tielinen L, Tarkkila P, Kontinen VK.

Analgesic effect of intraoperative intravenous S-ketamine in opioid-naïve patients

after major lumbar fusion surgery is temporary and not dose-dependent: a

randomized, double-blind, placebo-controlled clinical trial. *Anesth Analg.*

2021;132:69–79.